Lead Product(s) : TGD001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TargED Biopharmaceuticals Doses First Participant in Phase 1 Trial Of TGD001
Details : TGD001 is a groundbreaking thrombolytic designed to break down clots of all sizes and compositions, being investigated for acute ischemic stroke and TTP.
Product Name : TGD001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : TGD001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SEFA-1024
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEFA-1024 is a novel chemically modified fatty acid derived from naturally occurring fatty acid EPA. Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with high plasma triglyceride ...
Product Name : SEFA-1024
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2020
Lead Product(s) : SEFA-1024
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SST-5058
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk.
Product Name : SST-5058
Product Type : Antibody
Upfront Cash : Inapplicable
July 21, 2020
Lead Product(s) : SST-5058
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable